Structure Therapeutics (GPCR) Expected to Announce Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.39) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. On average, analysts expect Structure Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $47.35 on Thursday. Structure Therapeutics has a 52-week low of $15.80 and a 52-week high of $94.90. The company has a market capitalization of $3.37 billion, a PE ratio of -54.42 and a beta of -1.50. The company has a fifty day moving average of $46.12 and a 200-day moving average of $55.43.

Institutional Trading of Structure Therapeutics

Hedge funds have recently modified their holdings of the business. State of Wyoming bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Structure Therapeutics during the fourth quarter worth $127,000. Cibc World Market Inc. bought a new position in Structure Therapeutics in the 4th quarter worth about $226,000. Stifel Financial Corp purchased a new position in Structure Therapeutics during the 4th quarter worth $336,000. Finally, Raymond James Financial Inc. bought a new position in Structure Therapeutics during the 2nd quarter worth about $129,000. Institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on GPCR shares. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group started coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Finally, HC Wainwright cut their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.